Device Clearance Outpaces Practice Governance

The clearance pathway works. The practice layer doesn’t yet.

Tempus AI just picked up its third FDA clearance for an AI tool that reads standard ECGs, this time to flag signs of pulmonary hypertension, joining earlier clearances for atrial fibrillation and low ejection fraction detection MobiHealthNews. The company frames it as an expansion of an existing cardiac AI portfolio rather than a novel submission, and the 510(k) mechanics bear that out BioSpace. For sponsors watching FDA’s slower, more deliberative posture on generative AI, this is the reminder that the conventional AI/ML pathway is mature, predictable, and still moving. If your product performs a defined diagnostic function on defined input data, the agency has a well-worn process for it.

The harder problem is what happens after clearance, and that’s where the Pharmacists’ Defence Association just staked out new ground. The PDA published guidance on AI use in pharmacy practice, explicitly naming the “new professional, clinical, legal and practical considerations” that the technology introduces once it’s in a pharmacist’s hands The Pharmaceutical Journal. This is not a device approval question. It’s a practice governance question, and it sits in a regulatory gap that device clearance was never designed to fill.

That gap is the decision point regulated organizations need to see clearly. A cleared device tells you the algorithm performed to spec against a validation set. It does not tell you how a pharmacist should weigh an AI flag against clinical judgment, what liability attaches when they don’t, or how a practice documents that decision trail for a later audit. The PDA guidance is the professional body stepping into that space precisely because FDA’s clearance letter stops short of it.

For compliance and technology leaders in life sciences, the practical implication is that a clean 510(k) is necessary but not sufficient. Tempus’s pathway to clearance is a template worth studying for device-level validation. The PDA’s move is the template for what has to sit alongside it: a practice-level AI management system that governs how clinicians actually use the tool day to day, who is accountable when it disagrees with a human, and how that decision is logged. ISO 42001 gives organizations a structure for exactly this layer, an AI management system built for ongoing use rather than a one-time clearance event.

The two threads point in the same direction from opposite ends. Device makers are proving the FDA pathway can absorb more AI-enabled products without regulatory redesign. Professional bodies are proving that absorption alone doesn’t answer the governance question their members face at the bedside or the pharmacy counter. Organizations that treat clearance as the finish line will find themselves exposed exactly where the PDA guidance is now pointing, in the daily judgment calls a cleared device doesn’t make for you.

The lesson for 2026 planning cycles is straightforward. Budget for practice governance as a separate line item from regulatory submission. The clearance gets you to market. It doesn’t get you through an audit of how your clinicians used the tool last Tuesday.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that device clearance and practice governance are distinct regulatory layers requiring separate organizational attention—is logically sound and well-supported by the two primary sour
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but the article could benefit from more specific references to the ISO 42001 standard and the exact nature of the PDA’s guidance.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the regulatory distinctions between FDA clearance (ISO 13485/MDR) and post-market practice governance (ISO 42001/EU AI Act), though it could explicitly cite ISO 42001’
Technical Accuracy	Llama	cleared. The article accurately describes the distinction between FDA clearance for AI/ML devices and the need for practice governance, highlighting the importance of ISO 42001 for AI management systems.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and contrasts the ‘clearance pathway’ and ‘practice governance’ as distinct problems, avoiding vendor hype by focusing on the limitations of clearance and the emerg
Novelty & Non-Duplication	Grok	held. The Tempus-plus-PDA pairing yields a usable cross-jurisdictional synthesis the wire has not run, but the clearance-vs-practice-governance thesis itself is stock digital-health framing and risks echoin
Validation	DeepSeek	cleared. The central claim that device clearance does not address post-market practice governance is strongly validated by the explicit gap between FDA’s 510(k) process and the professional guidance issued by

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.